Full Text:   <2759>

CLC number: 

On-line Access: 2021-02-03

Received: 2020-08-19

Revision Accepted: 2020-11-16

Crosschecked: 0000-00-00

Cited: 0

Clicked: 3782

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
Open peer comments

Bio-Design and Manufacturing  2021 Vol.4 No.3 P.490-505

http://doi.org/10.1007/s42242-020-00114-3


Peptides-based vaccine against SARS-nCoV-2 antigenic fragmented synthetic epitopes recognized by T cell and ?-cell initiation of specific antibodies to fight the infection


Author(s):  Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, P.O. Box 715, Mecca 21955, Kingdom of Saudi Arabia, Science and Technology Unit, Umm Al-Qura University, P.O. Box 715, Mecca 21955, Kingdom of Saudi Arabia, The Regional Laboratory, Molecular Diagnostics Unit, Department of Molecular Biology, Ministry of Health (MOH), P.O. Box 6251, Mecca, Kingdom of Saudi Arabia, Department of Pathology and Lab Medicine, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada

Affiliation(s):  School of Automation Science and Electrical Engineering, Beihang University, Beijing 100191, China; more

Corresponding email(s):   zaabduljaleel@uqu.edu.sa, zainulbio@gmail.com

Key Words:  COVID-19, SARS-nCoV-2, Peptide-based vaccine, Cell-penetrating peptides, Lipid membrane, Vaccine efficacy


Share this article to: More

Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, P.O. Box 715, Mecca 21955, Kingdom of Saudi Arabia; Science and Technology Unit, Umm Al-Qura University, P.O. Box 715, Mecca 21955, Kingdom of Saudi Arabia; The Regional Laboratory, Molecular Diagnostics Unit, Department of Molecular Biology, Ministry of Health (MOH), P.O. Box 6251, Mecca, Kingdom of Saudi Arabia; Department of Pathology and Lab Medicine, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada. Peptides-based vaccine against SARS-nCoV-2 antigenic fragmented synthetic epitopes recognized by T cell and ?-cell initiation of specific antibodies to fight the infection[J]. Journal of Zhejiang University Science D, 2021, 4(3): 490-505.

@article{title="Peptides-based vaccine against SARS-nCoV-2 antigenic fragmented synthetic epitopes recognized by T cell and ?-cell initiation of specific antibodies to fight the infection",
author="Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, P.O. Box 715, Mecca 21955, Kingdom of Saudi Arabia; Science and Technology Unit, Umm Al-Qura University, P.O. Box 715, Mecca 21955, Kingdom of Saudi Arabia; The Regional Laboratory, Molecular Diagnostics Unit, Department of Molecular Biology, Ministry of Health (MOH), P.O. Box 6251, Mecca, Kingdom of Saudi Arabia; Department of Pathology and Lab Medicine, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada",
journal="Journal of Zhejiang University Science D",
volume="4",
number="3",
pages="490-505",
year="2021",
publisher="Zhejiang University Press & Springer",
doi="10.1007/s42242-020-00114-3"
}

%0 Journal Article
%T Peptides-based vaccine against SARS-nCoV-2 antigenic fragmented synthetic epitopes recognized by T cell and ?-cell initiation of specific antibodies to fight the infection
%A Department of Medical Genetics
%A Faculty of Medicine
%A Umm Al-Qura University
%A P.O. Box 715
%A Mecca 21955
%A Kingdom of Saudi Arabia
%A Science and Technology Unit
%A Umm Al-Qura University
%A P.O. Box 715
%A Mecca 21955
%A Kingdom of Saudi Arabia
%A The Regional Laboratory
%A Molecular Diagnostics Unit
%A Department of Molecular Biology
%A Ministry of Health (MOH)
%A P.O. Box 6251
%A Mecca
%A Kingdom of Saudi Arabia
%A Department of Pathology and Lab Medicine
%A University of Ottawa
%A 451 Smyth Road
%A Ottawa
%A ON K1H 8M5
%A Canada
%J Journal of Zhejiang University SCIENCE D
%V 4
%N 3
%P 490-505
%@ 1869-1951
%D 2021
%I Zhejiang University Press & Springer
%DOI 10.1007/s42242-020-00114-3

TY - JOUR
T1 - Peptides-based vaccine against SARS-nCoV-2 antigenic fragmented synthetic epitopes recognized by T cell and ?-cell initiation of specific antibodies to fight the infection
A1 - Department of Medical Genetics
A1 - Faculty of Medicine
A1 - Umm Al-Qura University
A1 - P.O. Box 715
A1 - Mecca 21955
A1 - Kingdom of Saudi Arabia
A1 - Science and Technology Unit
A1 - Umm Al-Qura University
A1 - P.O. Box 715
A1 - Mecca 21955
A1 - Kingdom of Saudi Arabia
A1 - The Regional Laboratory
A1 - Molecular Diagnostics Unit
A1 - Department of Molecular Biology
A1 - Ministry of Health (MOH)
A1 - P.O. Box 6251
A1 - Mecca
A1 - Kingdom of Saudi Arabia
A1 - Department of Pathology and Lab Medicine
A1 - University of Ottawa
A1 - 451 Smyth Road
A1 - Ottawa
A1 - ON K1H 8M5
A1 - Canada
J0 - Journal of Zhejiang University Science D
VL - 4
IS - 3
SP - 490
EP - 505
%@ 1869-1951
Y1 - 2021
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1007/s42242-020-00114-3


Abstract: 
The World Health Organization has declared the rapidly spreading coronavirus to be a global pandemic. The FDA is yet to approve a vaccine for human novel coronavirus. Here, we developed a peptide-based vaccine and used high-throughput screening by molecular dynamics simulation to identify T-cell- and ?-cell-recognized epitopes for producing specific antibodies against SARS-nCoV-2. We construct?~?12 P? antigenic epitope peptides to develop a more effective vaccine and identify specific antibodies. These epitope peptides selectively presented the best antigen presentation scores for both human pMHC class I and II alleles to develop a strong binding affinity. All antigens identified of SARS-nCoV-2 different proteins by each attached specific?~?17 L linker adaptor were used to construct a broad single peripheral peptide vaccine. It is expected to be highly antigenic with a minimum allergic effect. As a result of these exciting outcomes, expressing a vaccine using the intimated peptide was highly promising and positive to be highly proposed as epitope-based peptide vaccine of specific antibody against SARS-nCoV-2 by initiating T cells and ?-cells. An in vitro study for the proposed peptide-based vaccine is mostly recommended. Further clinical trials are required to check the efficacy of this vaccine.

沙特麦加大学Abduljaleel等 | 基于多肽的新冠疫苗,抗原片段化合成表位可被T细胞和β细胞识别来产生特异性抗感染抗体

本研究论文聚焦基于多肽的新冠疫苗开发。世界卫生组织宣布,快速传播的冠状病毒将成为全球大流行。FDA还没有批准人类新型冠状病毒疫苗。在这里,我们开发了一种基于多肽的疫苗,并使用分子动力学模拟高通量筛选寻找T细胞和β细胞识别的表位来产生特异性抗体来对抗新冠病毒。我们构建了约12个P抗原表位多肽,以开发更有效的疫苗并鉴定特异性抗体。这些表位多肽选择性地呈现了两种人类pMHC I类和II类等位基因的最佳抗原呈递分数,因此具有很强的结合亲和力。来自新冠不同蛋白的所有抗原被各自附着的特异的1–7 L连接子适配从而被用来构建广泛的单一外周多肽疫苗。我们可以预计此疫苗具有高度抗原性以及最低的过敏反应。这些令人兴奋的结果表明亲和多肽是一种很有前景有望通过启动T细胞和β细胞来对抗新冠的特异性抗原表位多肽疫苗。对于这类基于多肽疫苗的体外研究是很必要的。这种疫苗的效力需要进一步的临床试验来验证。

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE